ReishiMax, mushroom based dietary supplement, inhibits adipocyte differentiation, stimulates glucose uptake and activates AMPK

BMC Complementary and Alternative Medicine

Volumn 11, Issue , 2011, Pages

  Thyagarajan Sahu, Anita ^a   Lane, Brandon ^a   Sliva, Daniel ^a,b,c  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FATTY ACID BINDING PROTEIN 4; FATTY ACID SYNTHASE; FATTY ACID TRANSPORTER; GANODERMA LUCIDUM EXTRACT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYSACCHARIDE; REISHIMAX; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL FACTOR;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVATION; ENZYME INHIBITION; GANODERMA LUCIDUM; GENE EXPRESSION; GLUCOSE TRANSPORT; LIPOGENESIS; MEDICINAL MUSHROOM; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADIPOGENESIS; ANIMAL; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; GANODERMA; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOLOGICAL FACTORS; BIOLOGICAL TRANSPORT; DIETARY SUPPLEMENTS; DOWN-REGULATION; ENZYME ACTIVATION; GANODERMA; GLUCOSE; HUMANS; MICE; OBESITY;

EID: 80052858533     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-11-74     Document Type: Article

References (81)

1. Smith PD, O'Halloran P, Hahn DL, Grasmick M, Radant L. Screening for obesity: clinical tools in evolution, a WREN study. Wisconsin Medical Journal 2010, 109(5):274-278. 3026048, 21066933.
2. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009, 121(6):21-33. 10.3810/pgm.2009.11.2074, 2879283, 19940414.
3. Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004, 3(8):695-710. 10.1038/nrd1469, 15286736.
4. McHugh MD. Fit or fat? A review of the debate on deaths attributable to obesity. Public Health Nurs 2006, 23(3):264-270. 10.1111/j.1525-1446.2006.230309.x, 16684205.
5. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303(3):235-241.
6. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005, 115(5):1111-1119. 1087185, 15864338.
7. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005, 96(9):939-949. 10.1161/01.RES.0000163635.62927.34, 15890981.
8. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 2005, 5(2):122-128. 10.1016/j.coph.2005.01.006, 15780819.
9. Frayn KN. Obesity and metabolic disease: is adipose tissue the culprit?. Proc Nutr Soc 2005, 64(1):7-13. 10.1079/PNS2004403, 15877917.
10. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6(10):772-783. 10.1038/nri1937, 16998510.
11. Schaffler A, Scholmerich J, Salzberger B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol 2007, 28(9):393-399. 10.1016/j.it.2007.07.003, 17681884.
12. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998, 78(3):783-809.
13. MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem 1995, 64:345-373. 10.1146/annurev.bi.64.070195.002021, 7574486.
14. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000, 14(11):1293-1307.
15. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996, 87(3):377-389. 10.1016/S0092-8674(00)81359-8, 8898192.
16. Rangwala SM, Lazar MA. Transcriptional control of adipogenesis. Annu Rev Nutr 2000, 20:535-559. 10.1146/annurev.nutr.20.1.535, 10940345.
17. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000, 16:145-171. 10.1146/annurev.cellbio.16.1.145, 11031233.
18. Kolehmainen M, Vidal H, Alhava E, Uusitupa MI. Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity. Obes Res 2001, 9(11):706-712. 10.1038/oby.2001.95, 11707537.
19. Farmer SR. Regulation of PPARgamma activity during adipogenesis. Int J Obes (Lond) 2005, 29(Suppl 1):S13-16.
20. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8(10):1224-1234. 10.1101/gad.8.10.1224, 7926726.
21. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4(4):611-617. 10.1016/S1097-2765(00)80211-7, 10549292.
22. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, Darlington GJ, Spiegelman BM. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999, 3(2):151-158. 10.1016/S1097-2765(00)80306-8, 10078198.
23. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001, 60(3):349-356. 10.1079/PNS2001110, 11681809.
24. Nawrocki AR, Scherer PE. Keynote review: the adipocyte as a drug discovery target. Drug Discov Today 2005, 10(18):1219-1230. 10.1016/S1359-6446(05)03569-5, 16213414.
25. Wasan KM, Looije NA. Emerging pharmacological approaches to the treatment of obesity. J Pharm Pharm Sci 2005, 8(2):259-271.
26. Curtis R, Geesaman BJ, DiStefano PS. Ageing and metabolism: drug discovery opportunities. Nat Rev Drug Discov 2005, 4(7):569-580. 10.1038/nrd1777, 15976816.
27. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846. 10.1038/nature05482, 17167471.
28. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414(6865):821-827. 10.1038/414821a, 11742415.
29. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108(8):1167-1174. 209533, 11602624.
30. Sliva D. Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther 2003, 2(4):358-364. 10.1177/1534735403259066, 14713328.
31. Sliva D. Cellular and physiological effects of Ganoderma lucidum (Reishi). Mini Rev Med Chem 2004, 4(8):873-879.
32. Sliva D. Ganoderma lucidum in cancer research. Leuk Res 2006, 30(7):767-768. 10.1016/j.leukres.2005.12.015, 16458355.
33. Wasser S. Reishi (Ganoderma lucidum). Encyclopedia of Dietary Supplements 2005, 603-622.
34. Thyagarajan A, Jiang J, Hopf A, Adamec J, Sliva D. Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int J Mol Med 2006, 18(4):657-664.
35. Thyagarajan A, Zhu J, Sliva D. Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int J Oncol 2007, 30(4):963-969.
36. Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 2006, 29(3):695-703.
37. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 2004, 49(2):209-216. 10.1207/s15327914nc4902_13, 15489214.
38. Jiang J, Slivova V, Valachovicova T, Harvey K, Sliva D. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol 2004, 24(5):1093-1099.
39. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun 2005, 330(1):46-52. 10.1016/j.bbrc.2005.02.116, 15781230.
40. Dudhgaonkar S, Thyagarajan A, Sliva D. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol 2009, 9(11):1272-1280. 10.1016/j.intimp.2009.07.011, 19651243.
41. Liu F, Kim J, Li Y, Liu X, Li J, Chen X. An extract of Lagerstroemia speciosa L. has insulin-like glucose uptake-stimulatory and adipocyte differentiation-inhibitory activities in 3T3-L1 cells. J Nutr 2001, 131(9):2242-2247.
42. Giri S, Rattan R, Haq E, Khan M, Yasmin R, Won JS, Key L, Singh AK, Singh I. AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab (Lond) 2006, 3:31.
43. Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, Unger RH. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 1997, 94(9):4637-4641. 10.1073/pnas.94.9.4637, 20776, 9114043.
44. Chakrabarti P, Kandror KV. FoxO1 controls insulin-dependent adipose triglyceride lipase (ATGL) expression and lipolysis in adipocytes. J Biol Chem 2009, 284(20):13296-13300. 10.1074/jbc.C800241200, 2679428, 19297333.
45. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, Fukushima Y, Onishi Y, Ono H, Yazaki Y, et al. No correlation of plasma cell 1 overexpression with insulin resistance in diabetic rats and 3T3-L1 adipocytes. Diabetes 1999, 48(7):1365-1371. 10.2337/diabetes.48.7.1365, 10389840.
46. Garcia de Herreros A, Birnbaum MJ. The acquisition of increased insulin-responsive hexose transport in 3T3-L1 adipocytes correlates with expression of a novel transporter gene. J Biol Chem 1989, 264(33):19994-19999.
47. Thyagarajan A, Jedinak A, Nguyen H, Terry C, Baldridge LA, Jiang J, Sliva D. Triterpenes From Ganoderma Lucidum Induce Autophagy in Colon Cancer Through the Inhibition of p38 Mitogen-Activated Kinase (p38 MAPK). Nutr Cancer 2010, 62(5):630-640. 10.1080/01635580903532390, 20574924.
48. Lafontan M. Advances in adipose tissue metabolism. Int J Obes (Lond) 2008, 32(Suppl 7):S39-51.
49. Auwerx J, Leroy P, Schoonjans K. Lipoprotein lipase: recent contributions from molecular biology. Crit Rev Clin Lab Sci 1992, 29(3-4):243-268. 10.3109/10408369209114602, 1489519.
50. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996, 10(9):1096-1107. 10.1101/gad.10.9.1096, 8654925.
51. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009, 9(5):407-416. 10.1016/j.cmet.2009.03.012, 19416711.
52. Carling D. The AMP-activated protein kinase cascade--a unifying system for energy control. Trends Biochem Sci 2004, 29(1):18-24. 10.1016/j.tibs.2003.11.005, 14729328.
53. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 2007, 47:185-210. 10.1146/annurev.pharmtox.47.120505.105304, 16879084.
54. CDC Obesity Trends Among U.S. Adults Between 1985 and 2009. 2009, CDC., http://www.cdc.gov/obesity/data/trends.html
55. Research NBoE The Increasing Prevalence of Obesity 2011, Research NBoE., http://www.nber.org/digest/jul08/w13181.html
56. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999, 282(16):1519-1522. 10.1001/jama.282.16.1519, 10546690.
57. Okosun IS, Chandra KM, Choi S, Christman J, Dever GE, Prewitt TE. Hypertension and type 2 diabetes comorbidity in adults in the United States: risk of overall and regional adiposity. Obes Res 2001, 9(1):1-9. 10.1038/oby.2001.1, 11346661.
58. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4(8):579-591. 10.1038/nrc1408, 15286738.
59. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144(9):3765-3773. 10.1210/en.2003-0580, 12933646.
60. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005, 115(5):911-919. quiz 920, 10.1016/j.jaci.2005.02.023, 15867843.
61. Warnke I, Goralczyk R, Fuhrer E, Schwager J. Dietary constituents reduce lipid accumulation in murine C3H10 T1/2 adipocytes: A novel fluorescent method to quantify fat droplets. Nutr Metab (Lond) 2011, 8(1):30.
62. Díaz-Delfín J, del Mar Gutiérrez M, Gallego-Escuredo JM, Domingo JC, Gracia MM, Villarroya F, Domingo P, Giralt M. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res 2011, 91(2):112-9. 10.1016/j.antiviral.2011.04.018, 21619898.
63. Lee H, Kang R, Bae S, Yoon Y. AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/β-catenin pathway in 3T3-L1 adipocytes. Int J Mol Med 2011, 28(1):65-71.
64. Ntambi JM, Young-Cheul K. Adipocyte differentiation and gene expression. J Nutr 2000, 130(12):3122S-3126S.
65. Hwang JT, Park IJ, Shin JI, Lee YK, Lee SK, Baik HW, Ha J, Park OJ. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 2005, 338(2):694-699. 10.1016/j.bbrc.2005.09.195, 16236247.
66. Sohle J, Knott A, Holtzmann U, Siegner R, Gronniger E, Schepky A, Gallinat S, Wenck H, Stab F, Winnefeld M. White Tea extract induces lipolytic activity and inhibits adipogenesis in human subcutaneous (pre)-adipocytes. Nutr Metab (Lond) 2009, 6:20.
67. Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010, 10:34. 10.1186/1472-6882-10-34, 2911406, 20587058.
68. Lee H, Kang R, Yoon Y. Shikonin inhibits fat accumulation in 3T3-L1 adipocytes. Phytother Res 2010, 24(3):344-351. 10.1002/ptr.2942, 19610030.
69. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 2010, 34(10):1546-1553.
70. Habinowski SA, Witters LA. The effects of AICAR on adipocyte differentiation of 3T3-L1 cells. Biochem Biophys Res Commun 2001, 286(5):852-856. 10.1006/bbrc.2001.5484, 11527376.
71. Ha do T, Trung TN, Phuong TT, Yim N, Chen QC, Bae K. The selected flavonol glycoside derived from Sophorae Flos improves glucose uptake and inhibits adipocyte differentiation via activation AMPK in 3T3-L1 cells. Bioorg Med Chem Lett 2010, 20(20):6076-6081. 10.1016/j.bmcl.2010.08.054, 20822902.
72. Ha do T, Nam Trung T, Bich Thu N, Van On T, Hai Nam N, Van Men C, Thi Phuong T, Bae K. Adlay seed extract (Coix lachryma-jobi L.) decreased adipocyte differentiation and increased glucose uptake in 3T3-L1 cells. J Med Food 2010, 13(6):1331-1339. 10.1089/jmf.2010.1155, 21091246.
73. Lee I, Seo J, Kim J, Kim H, Youn U, Lee J, Jung H, Na M, Hattori M, Min B, et al. Lanostane triterpenes from the fruiting bodies of Ganoderma lucidum and their inhibitory effects on adipocyte differentiation in 3T3-L1 Cells. J Nat Prod 2010, 73(2):172-176. 10.1021/np900578h, 20039640.
74. Lee I, Kim H, Youn U, Kim J, Min B, Jung H, Na M, Hattori M, Bae K. Effect of lanostane triterpenes from the fruiting bodies of Ganoderma lucidum on adipocyte differentiation in 3T3-L1 cells. Planta Med 2010, 76(14):1558-1563. 10.1055/s-0030-1249827, 20422507.
75. Lee I, Kim J, Ryoo I, Kim Y, Choo S, Yoo I, Min B, Na M, Hattori M, Bae K. Lanostane triterpenes from Ganoderma lucidum suppress the adipogenesis in 3T3-L1 cells through down-regulation of SREBP-1c. Bioorg Med Chem Lett 2010, 20(18):5577-5581. 10.1016/j.bmcl.2010.06.093, 20702092.
76. Sliva D. Medicinal potential of Ganoderma lucidum. Applied Mycology 2009, 173-196. Bridge, PD: CAB International, Rai M.
77. Adamec J, Jannasch A, Dudhgaonkar S, Jedinak A, Sedlak M, Sliva D. Development of a new method for improved identification and relative quantification of unknown metabolites in complex samples: determination of a triterpenoid metabolic fingerprint for the in situ characterization of Ganoderma bioactive compounds. J Sep Sci 2009, 32(23-24):4052-4058.
78. Jung KH, Ha E, Kim MJ, Uhm YK, Kim HK, Hong SJ, Chung JH, Yim SV. Ganoderma lucidum extract stimulates glucose uptake in L6 rat skeletal muscle cells. Acta Biochim Pol 2006, 53(3):597-601.
79. Shimojo Y, Kosaka K, Shirasawa T. Effect of Ganoderma lucidum extract on adipocyte differentiation and adiponectin gene expression in the murine pre-adipocyte cell line, 3T3-L1. Phytother Res 2010, 25(2):202-207.
80. Chu TT, Benzie IF, Lam CW, Fok BS, Lee KK, Tomlinson B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr 2011, 1-11.
81. Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP, Ho NW. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 2003, 9(4):491-497. 10.1089/107555303322284776, 14499024.